参考文献/References:
[1]. 付准, 杨毅宁. 长链非编码RNA与心血管疾病发展关系的研究进展[J]. 心血管病学进展,2018,39(2):275-278.
[2] Zhang CY, Liu M, Wan JM, et al. Role of noncoding RNA in pulmonary arterial hypertension and potential drug therapeutic target[J]. Curr Top Med Chem,2018,18(12):975-986.
[3] Martens L,Rühle F,Stoll M. LncRNA secondary structure in the cardiovascular system[J]. Noncoding RNA Res,2017,2(3-4):137-142.
[4] Sun Z,Liu Y,Yu F.Long non-coding RNA and mRNA profile analysis of metformin to reverse the pulmonary hypertension vascular remodeling induced by monocrotaline[J]. Biomed Pharmacother,2019,115:108933
[5] Su H,Xu X,Yan C,et al. LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension[J]. Respir Res,2018,19(1):254
[6] Jandl K,Thekkekara Puthenparampil H,Marsh LM,et al. Long non-coding RNAs influence the transcriptome in pulmonary arterial hypertension:the role of PAXIP1-AS1[J]. J Pathol,2019,247(3):357-370.
[7] Zhu TT,Sun RL,Yin YL,et al. Long noncoding RNA UCA1 promotes the proliferation of hypoxic human pulmonary artery smooth muscle cells[J]. Pflugers Arch,2019,471(2):347-355.
[8] Zhang H,Liu Y,Yan L,et al. Long noncoding RNA Hoxaas3 contributes to hypoxia-induced pulmonary artery smooth muscle cell proliferation[J]. Cardiovasc Res,2019,115(3):647-657.
[9] Chen J,Guo J,Cui X,et al. The long noncoding RNA LnRPT is regulated by PDGF-BB and modulates the proliferation of pulmonary artery smooth muscle cells[J]. Am J Respir Cell Mol Biol,2018,58(2):181-193.
[10] Bischoff FC,Werner A,John D,et al. Identification and functional characterization of hypoxia-induced endoplasmic reticulum stress regulating lncRNA (HypERlnc) in pericytes[J]. Circ Res,2017,121(4):368-375.
[11] Sharma S,Findlay GM,Bandukwala HS,et al. Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex[J]. Proc Natl Acad Sci USA,2011,108(28):11381-11386.
[12] Leung A,Trac C,Jin W,et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells[J]. Circ Res,2013,13(3): 266-278.
[13] Josipovic I,Fork C,Preussner J,et al. PAFAH1B1 and the lncRNA NONHSAT073641 maintain an angiogenic phenotype in human endothelial cells[J]. Acta Physiol (Oxf),2016,218(1):13-27.
[14] Gong J,Chen Z,Chen Y,et al. Long non-coding RNA CASC2 suppresses pulmonary artery smooth muscle cell proliferation and phenotypic switch in hypoxia-induced pulmonary hypertension[J]. Respir Res,2019,20(1):53.
[15] Zhu B,Gong Y,Yan G,et al. Down-regulation of lncRNA MEG3 promotes hypoxia-induced human pulmonary artery smooth muscle cell proliferation and migration via repressing PTEN by sponging miR-21[J]. Biochem Biophys Res Commun,2018,495(3):2125-2132.
[16] Sun Z,Nie X,Sun S,et al. Long non-coding RNA MEG3 downregulation triggers human pulmonary artery smooth muscle cell proliferation and migration via the p53 signaling pathway[J]. Cell Physiol Biochem,2017,42(6):2569-2581.
[17] Liu Y,Sun Z,Zhu J,et al. LncRNA-TCONS_00034812 in cell proliferation and apoptosis of pulmonary artery smooth muscle cells and its mechanism[J]. J Cell Physiol,2018,233(6):4801-4814.
[18] Han B,Bu P,Meng X,et al. Microarray profiling of long non-coding RNAs associated with idiopathic pulmonary arterial hypertension[J]. Exp Ther Med,2017,13(6):2657-2666.
[19] Gu S,Li G,Zhang X,et al. Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension[J]. Mol Med Rep,2015,11(4):2631-2643.
[20] Cao Y,Yang Y,Wang L,et al. Analyses of long non-coding RNA and mRNA profiles in right ventricle myocardium of acute right heart failure in pulmonary arterial hypertension rats[J]. Biomed Pharmacother,2018,106:1108-1115.
[21] Wang X,Yan C,Xu X,et al. Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model[J]. Gene,2016,579(1):23-28.
[22] Schlosser K,Hanson J,Villeneuve PJ,et al. Assessment of circulating lncRNAs under physiologic and pathologic conditions in humans reveals potential limitations as biomarkers[J]. Sci Rep,2016,6:36596.
[23]金光军,周冰之,张建成. miR-21降解PTEN影响香烟提取物诱导的PASMCs的增殖与迁移[J]. 医学研究杂志,2019,48(1):47-51,73.
[24] Leisegang MS,Fork C,Josipovic I,et al. Long noncoding RNA MANTIS facilitates endothelial angiogenic function[J]. Circulation,2017,136(1):65-79.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(6):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(6):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[4]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[5]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[6]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[7]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[8]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(6):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[9]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[10]刘雪鸢 徐燕萍 殷跃辉.交感神经去除术在肺动脉高压治疗中的研究进展[J].心血管病学进展,2020,(5):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]
LIU Xueyuan,XU Yanping,YIN Yuehui.Sympathetic Denervation in Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]